Reference health
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
1 of 85 checkable references need attention · checked 2026-08-10
At the dated check, the references listed below either did not resolve in Crossref or DataCite, or carried a retraction notice. Each one is shown with the registry record that put it there.
5 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
References needing attention
does not resolve to a known work10.3389/fen-do.2019.00441
The 84 checked references that resolve
resolves10.1172/JCI112981
Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.
resolves10.1021/jm701272q
Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
resolves10.2337/dc15-0642
Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport
resolves10.1111/dom.12670
Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis
resolves10.1016/j.diabet.2020.01.002
Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials
resolves10.1007/s13300-019-0674-7
Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in East Asians with Type 2 Diabetes: A Systematic Review and Meta-Analysis
resolves10.3389/fendo.2020.00190
Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes
resolves10.1038/srep44128
The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis
resolves10.1002/oby.22066
The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta‐Analysis
resolves10.1186/s12933-019-0852-y
Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy
resolves10.2337/dc18-2207
Ambulatory Blood Pressure Reduction With SGLT-2 Inhibitors: Dose-Response Meta-analysis and Comparative Evaluation With Low-Dose Hydrochlorothiazide
resolves10.1001/jamacardio.2020.4511
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
resolves10.1161/JAHA.120.019463
Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized‐Controlled Trials
resolves10.1056/NEJMoa1911303
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
resolves10.1016/S0140-6736(20)31824-9
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
resolves10.1056/NEJMoa2030183
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
resolves10.1111/dom.14470
<scp>Sodium‐glucose cotransporter‐2</scp>
inhibitors for type 2 diabetes mellitus in adults: An overview of 46 systematic reviews
resolves10.2337/dc19-0349
Progressive Decline in Estimated Glomerular Filtration Rate in Patients With Diabetes After Moderate Loss in Kidney Function—Even Without Albuminuria
resolves10.1038/s41598-020-63443-4
Prevalence and Risk Factors of Chronic Kidney Disease among Type 2 Diabetes Patients: A Cross-Sectional Study in Primary Care Practice
resolves10.1159/000490959
Chapter 1 UK Renal Replacement Therapy Adult Incidence in 2016: National and Centre-specific Analyses
resolves10.1016/S2213-8587(17)30104-3
Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
resolves10.1007/s40620-020-00803-3
Blood pressure reduction and RAAS inhibition in diabetic kidney disease: therapeutic potentials and limitations
resolves10.1056/NEJMoa1504720
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
resolves10.1016/S2213-8587(19)30180-9
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
resolves10.1007/s00125-021-05407-5
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
resolves10.1159/000503919
The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis
resolves10.1016/S0140-6736(18)32590-X
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
resolves10.1111/dom.13648
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis
resolves10.1681/ASN.2020050723
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial
resolves10.1161/CIRCULATIONAHA.120.050391
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction
resolves10.1161/CIRCULATIONAHA.120.051824
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status
resolves10.1161/CIRCULATIONAHA.113.005081
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
resolves10.1161/JAHA.119.016173
Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo‐Controlled Trial
resolves10.2337/dc20-2604
Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial
resolves10.1002/ejhf.2066
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
resolves10.1186/s40360-017-0125-x
Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes
resolves10.1371/journal.pone.0159335
Chronic Kidney Disease, Fluid Overload and Diuretics: A Complicated Triangle
resolves10.1016/S2213-8587(20)30382-X
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial
resolves10.1016/j.kint.2017.12.027
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
resolves10.1161/HYPERTENSIONAHA.119.11684
Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
resolves10.1507/endocrj.EJ20-0222
Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration
resolves10.1152/ajprenal.00120.2019
Knockout of Na<sup>+</sup>-glucose cotransporter SGLT1 mitigates diabetes-induced upregulation of nitric oxide synthase NOS1 in the macula densa and glomerular hyperfiltration
resolves10.1038/s41581-020-0256-y
The tubular hypothesis of nephron filtration and diabetic kidney disease
resolves10.1259/bjr.20190562
Non-invasive assessment of early stage diabetic nephropathy by DTI and BOLD MRI
resolves10.1161/CIRCULATIONAHA.119.044235
Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
resolves10.1053/j.ajkd.2020.04.016
Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics
resolves10.1038/s41419-020-2544-7
Sodium–glucose cotransporter 2 inhibition suppresses HIF-1α-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice
resolves10.1038/nm.3762
Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development
resolves10.1152/ajprenal.00497.2018
Effect of renal tubule-specific knockdown of the Na<sup>+</sup>/H<sup>+</sup>exchanger NHE3 in Akita diabetic mice
resolves10.1007/s00125-019-4859-4
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
resolves10.1007/s00125-021-05424-4
Sodium–glucose cotransporter 2 inhibitors and risk of nephrolithiasis
resolves10.1007/s11886-019-1165-1
Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure
resolves10.1136/bmjopen-2018-022577
Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
resolves10.2215/CJN.01120211
Acute Kidney Injury Episodes and Chronic Kidney Disease Risk in Diabetes Mellitus
resolves10.1053/j.ajkd.2015.02.338
A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury
resolves10.1111/dom.13754
Acute kidney injury with sodium‐glucose co‐transporter‐2 inhibitors: A meta‐analysis of cardiovascular outcome trials
resolves10.1371/journal.pmed.1002983
Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis
resolves10.1016/j.cardfail.2012.10.010
Congestive Renal Failure: The Pathophysiology and Treatment of Renal Venous Hypertension
resolves10.1038/ki.2014.226
Hyperglycemia, p53, and mitochondrial pathway of apoptosis are involved in the susceptibility of diabetic models to ischemic acute kidney injury
resolves10.1111/j.1440-1797.2009.01170.x
Renoprotective effects of asialoerythropoietin in diabetic mice against ischaemia–reperfusion‐induced acute kidney injury
resolves10.1152/ajprenal.00533.2012
TNF-α mediates increased susceptibility to ischemic AKI in diabetes
The 5 references without a DOI — listed, not checked
no DOI — not checkedGheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2016;5:49–56.
no DOI — not checkedCanagliflozin prescribing information, USA. 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204042s011lbl.pdf. Accessed 2 July 2021.
no DOI — not checkedDapagliflozin prescribing information, USA. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202293s020lbl.pdf. Accessed 2 July 2021.
no DOI — not checkedEmpagliflozin prescribing information, USA. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204629s023lbl.pdf. Accessed 2 July 2021.
no DOI — not checkedErtugliflozin prescribing information, USA. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209803s000lbl.pdf. Accessed 2 July 2021.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-08-10 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1007/s11892-021-01442-z"><img src="https://citestamp.com/citestamped/10.1007/s11892-021-01442-z/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1007/s11892-021-01442-z)